Business
OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results
Conference call begins at 4:30 p.m. Eastern time todayMIAMI, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces financial guidance for the first quarter and full year 2026. Highlights from the fourth quarter of 2025 and recent weeks include the following: Entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies
About this update from Opko Health, Inc.
[{"type":"image","alt":"OPKO Health, Inc.","displaySize":"","headline":null,"caption":"OPKO Health, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/b17914b826278f91fa68691266a03f35"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/2OiZoOrClmqtm95qDejWBw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b17914b826278f91fa68691266a03f35","width":300,"height":300}},"lazy":false},{"type":"text","content":"Conference call begins at 4:30 p.m. Eastern time today","length":54,"tagName":"p"},{"type":"text","content":"MIAMI, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces financial guidance for the first quarter and full year 2026.","length":258,"tagName":"p"},{"type":"text","content":"Highlights from the fourth quarter of 2025 and recent weeks include the following:","length":82,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies. This new partnership leverages ModeX’s MSTAR technology platform with Regeneron’s proprietary binders to develop single molecule candidates that target multiple distinct biological pathways in several clinical indications. ModeX received an upfront payment and is entitled to potential milestone payments exceeding $200 million for each program. The overall potential value of the collaboration exceeds $1 billion if multiple products from the collaboration are successful. In addition, ModeX is eligible to receive tiered royalties on global net sales, reaching low double digits at the highest tier. Regeneron is responsible for funding all preclinical and clinical development, as well as all commercialization activities.","length":831,"tagName":"p"}]},{"val":[{"type":"text","content":"Merck completed the Phase 1 Epstein-Barr virus vaccine trial (NCT06655324). This investigational vaccine candidate is being developed in collaboration with Merck. The Phase 1 trial evaluating safety and tolerability in over 200 healthy adults was completed in the fourth quarter of 2025. Additional studies are in progress to inform dose and adjuvant sele...